Filter by: patients
Home > Community Treatment Reports and Side Effects > Lofepramine Treatment Report
What is Lofepramine?

Lofepramine is a third generation tricyclic antidepressant used in the treatment of depressive disorders. It has both antidepressant and anxiolytic properties.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Depressed mood 4 1 Efficacy_moderate
Treat my mood condition(s) 3 2 Efficacy_moderate Efficacy_none
Major Depressive Disorder 1 0

See all 8 patients currently taking Lofepramine

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 2
None
 1

Commonly reported side effects, conditions, and hospitalizations associated with Lofepramine

Cold hands 1
Cold hands and feet 1
Loss of interest in food 1

Reported Dosages

  140 mg daily 210 mg daily 280 mg daily
  2 Number of Patients: 2 5 Number of Patients: 5 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Lofepramine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 100%

See all 1 patient who’ve stopped taking Lofepramine

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Lofepramine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Lofepramine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Lofepramine

Always
 2 67%
Usually
 1 33%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Lofepramine

Very
 0 0%
Somewhat
 0 0%
A little
 2 67%
Not at all
 1 33%

Cost

Paid out of pocket

Cost of Lofepramine

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 2 100%

Report created on May 28, 2012.